Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (204)	1/15/2003 7:21:29 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PTIE Was up 33.62% on volume of 378,549 (about 6.5x its daily average)after it announced a licensing agreement with DRRX, to formulate certain long-acting opioid drugs. Under the agreement, PTIE paid DRRS an undisclosed upfront fee and has exclusive worldwide rights to develop its opioid drugs with DRRS's gel- cap SABER technology. (The market for opioid drugs reportedly was more than $3 billion in 2002.) PTIE seems to have formed a base at the $2.25 level siliconinvestor.com It needs to close above its Dec. 2 H of 3.93.(It has been on a pretty steady down-trend since its April 2002 H of 12.12) siliconinvestor.com The downtrend on its weekly chart has not been broken yet. siliconinvestor.com Bernard